Cancer risk among staff at two radiotherapy departments in Denmark.
Journal - The British journal of radiology (ENGLAND )
In comparison with the general Danish population, the relative risk (RR) for cancer among staff members employed in two radiotherapy departments in Denmark during 1954-1982 and alive on 1 April 1968 was assessed by linkage to the Danish Cancer Registry. All staff had been monitored with film dosimeters for exposure to radiation. The study cohort consisted of 4151 persons, accruing 49553 person-years at risk. The collective radiation dose was 76.54 manSv and the mean dose 18.4 mSv. A total of 163 cancer cases were observed with 152.3 expected. The risks for cancers usually considered to be radiogenic were not elevated. A significant excess of prostatic cancer was observed (five cases, relative risk, 6.02; 95% confidence interval, 1.94-14.06); this is likely to be a chance finding. No relation was observed between radiation dose or years of exposure and cancer risk, but a weak non-significant increase in risk with time since first exposure was seen.
|ISSN : ||0007-1285|
|Mesh Heading : ||Adult Cohort Studies Denmark Female Humans Male Neoplasms Neoplasms, Radiation-Induced Occupational Diseases Occupational Exposure Personnel, Hospital Radiation Dosage Radiology Department, Hospital Risk Time Factors radiotherapy adverse effects|
|Mesh Heading Relevant : ||epidemiology epidemiology statistics & numerical data manpower|
Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
Journal - Acta oncologica (Stockholm, Sweden) (SWEDEN )
A phase II trial in postmenopausal women with advanced breast cancer naive to cytotoxic treatment for recurrent disease was performed with a combinated chemo-endocrine regimen of prednimustine, methotrexate, mitoxantrone, 5-fluorouracil, and tamoxifen. Thus we replaced the most toxic agents--cyclophosphamide and doxorubicin often used in combinations--with prednimustine and mitoxantrone respectively, which are supposed to be equally efficient but less toxic. Seventy-seven patients were registered but 6 were ineligible. Complete response was obtained in 11%, partial response in 29%, no change in 29%, and progressive disease in 31%. Median duration of response was 18.5 months, time to disease progression 9.2 months, and survival 16.0 months. Toxicity was modest; 61% had no or only moderate alopecia not necessitating a wig, 59% had no or only moderate, if any, nausea. Bone marrow suppression, especially thrombopenia, was a major dose limiting factor. This regimen seems to be effective and have low toxicity in advanced breast cancer in postmenopausal women.
|ISSN : ||0284-186X|
|Mesh Heading : ||Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Drug Evaluation Female Fluorouracil Follow-Up Studies Humans Menopause Methotrexate Middle Aged Mitoxantrone Prednimustine Tamoxifen adverse effects radiotherapy surgery administration & dosage administration & dosage administration & dosage administration & dosage administration & dosage|
|Mesh Heading Relevant : ||therapeutic use drug therapy|